Summary of COVID-19 artemisinin studies
Studies
Meta Analysis
Hide extended summaries
43 patient artemisinin late treatment study: 31% faster recovery (p=0.02), 8% shorter hospitalization (p=0.22), and 29% faster viral clearance (p=0.05).
Prospective study of 43 hospitalized COVID-19 patients in China showing faster symptom improvement and shorter hospitalization with artesunate. Artesunate 60 mg twice daily for 10 days.
Apr 2020, China Critical Care Medicine, https://rs.yiigle.com/cmaid/1203190, https://c19p.org/lin7
RCT 60 mild-moderate COVID-19 patients showing faster recovery with artemisinin.
Jan 2021, medRxiv, https://www.medrxiv.org/content/10.1101/2021.01.24.21250418, https://c19p.org/trieu
Very high COI low-risk patient RCT in South Africa, showing no significant differences with artesunate-amodiaquine or pyronaridine-artesunate.
Oct 2022, eBioMedicine, https://www.sciencedirect.com/science/article/pii/S2352396422005047, https://c19p.org/chandiwanaart
43 patient artemisinin late treatment study: 31% faster recovery (p=0.02), 8% shorter hospitalization (p=0.22), and 29% faster viral clearance (p=0.05).
Prospective study of 43 hospitalized COVID-19 patients in China showing faster symptom improvement and shorter hospitalization with artesunate. Artesunate 60 mg twice daily for 10 days.
Apr 2020, China Critical Care Medicine, https://rs.yiigle.com/cmaid/1203190, https://c19p.org/lin7
2. Trieu et al., Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19
60 patient artemisinin early treatment RCT: 52% improved recovery (p=0.08).RCT 60 mild-moderate COVID-19 patients showing faster recovery with artemisinin.
Jan 2021, medRxiv, https://www.medrxiv.org/content/10.1101/2021.01.24.21250418, https://c19p.org/trieu
3. Chandiwana et al., Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial
114 patient artemisinin early treatment RCT: 29% lower progression (p=0.66), 27% faster recovery (p=0.1), and 1% worse viral clearance (p=0.76).Very high COI low-risk patient RCT in South Africa, showing no significant differences with artesunate-amodiaquine or pyronaridine-artesunate.
Oct 2022, eBioMedicine, https://www.sciencedirect.com/science/article/pii/S2352396422005047, https://c19p.org/chandiwanaart
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.